Q1 2026 · 13F-HR
BIOS Capital Management, LPholdings as filed
Filed 2026-05-13 · accession 0001813845-26-000003
$52.9M
Reported value
6
Positions
2026-03-31
Period end
The Brief · BIOS Capital Management, LP · Q1 2026
AI · grounded in 13F
BIOS Capital Management, LP reduced its position in INAB by 33.78%. The fund also trimmed its holding in LTRN by 14.37%. Conversely, it accumulated more shares of RNTX, increasing that position by 17.25%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 005083100 | ACTU | ACTUATE THERAPEUTICS INC | $27.5M | 52.1% | 10,049,996 | Common | SHARED |
| 67577R102 | IRD | OPUS GENETICS INC | $16.8M | 31.7% | 3,683,429 | Common | SHARED |
| 19243B102 | CGTX | COGNITION THERAPEUTICS INC | $4.6M | 8.63% | 6,000,000 | Common | SHARED |
| 00887A204 | RNTX | REIN THERAPEUTICS INC | $2.6M | 4.87% | 1,982,375 | Common | SHARED |
| 51654W101 | LTRN | LANTERN PHARMA INC | $1.2M | 2.24% | 864,435 | Common | SHARED |
| 45674E208 | INAB | IN8BIO INC | $248,351 | 0.47% | 167,805 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.